451
www.praktickelekarenstvi.cz550715901901162343533734615075796446977287978629369681044111011831228130213851441149115661598162416941761
e3497617148020186176266
PRAKTICKÉ80737159019080160258338422459552632710
LÉKÁRENSTVÍ88197159019074149229330411488590663741833870
AKTUÁLNÍ71882940227122239349476597693822881
FARMAKOTERAPIE81062940227100218330490615733863967106811841312142214781582
Nežádoucí5421508018869124183255323394465525554
účinky6001508018871130159230291358
kombinované6386508018861127221283312383453517580651705
imunoterapie7117508018829123193264334386441502575634662716
u7860508018870
nádoru7957508018871140208278340411
ledvin,8394508018853108177241270341367
plic8786508018860112142201
a9014508018869
melanomu9109508018894148202274345415509579
and550876015559127196
kinetics77587601555583150212251276333381
of1185876015569102
response131587601553999146215285353399461
with1805876015594120159227
ipilimumab.206087601552797123148173277344449506576596
J2684876015545
Clin275887601557499124191
Oncol.2978876015587156213278305326
2012;30(21):2691-2697.3333876015563124179231251313375408468523546565628687747803835889948100810661074
21.5501034015767126145
Topalian7231036015563123193252277302359426
SL,11781036015562117139
Hodi13461036015584152223248
FS,16231036015562118138
Brahmer17901036015568104163231335397434
JR,22521036015547111135
et24151036015565104
al.2547103601556187108
Safety,26841036015562120153214252312327
activity,30401036015561118160185243269308368383
and34511036015562129199
immune36781036015530134238305373435
correlates41411036015561126163201261287344382441488
of46581036015571104
anti-47901036015561129166192230
-PD-15501196015539105185227281
antibody8591196015559127164189259328399455
in1343119601552795
cancer.14661196015558116184241300337353
N18471196015583
Engl19591196015560127197222
J22101196015545
Med.228311960155101164234256
2012;366(26):2443-2454.256711960155641241802322523143754394715315906216407037588258829209741030108711501170
22.5501354015767132158
Khoja7361356015565135204230286
L,1051135601555880
Day11601356015584141195
D,13831356015584101
Wei-Wu151313560155106165190229333398
Chen19401356015574141203271
T,2239135601556174
et23411356015563102
al.2471135601555985106
Tumour-26051356015561119224292360396430
and30631356015559127196
class-specific3288135601555883140186233269316385449507532562593650
patterns39671356015571130167210269306375421
of44161356015569102
immune-45471356015527131235302370432473
-related550151601553977137163220258317388
adverse9661516015555125183243280328390
events13841516015559116177245282330
of1743151601556598
immune18691516015523128232299367429
checkpoint23261516015554122184242295367436462530567
inhibitors:2921151601552391158183253279318383421468489
a34381516015555
systematic35211516015549107154194254359416453479535
review.4085151601553494151178239331348
Ann44621516015572140207
Oncol.46981516015583152209274301322
2017;8(10):2377-2385.550167601556312417923024530834039645148250156362568274377482889095110111030
23.5501834015767132157
Berner7351836015576138175244306342
F,1106183601556976
Bomze12111836015575144249301361
D,16011836015593110
Diem17401836015593119181285
S,2054183601557091
et21731836015572111
al.2313183601556894115
Association24561836015586135181250308333389427452520588
of30731836015578111
Checkpoint32131836015583151213271324396466492559596
Inhibitor-Induced38381836015536104172197267293332397434468496564634700757817888
Toxic47541836015570130183209265
Effects550199601556193128189247289337
With91619960155102129168236
Shared11801996015556124181217277348
Cancer15561996015570128195252312348
and19321996015555123192
Tissue2153199601555685130176242304
Antigens24861996015571139176202271333400446
in2961199601552290
Non-Small30791996015579147216254309413470496521
Cell36281996015570130156181
Lung38371996015554120187257
Cancer.41221996015570128196253312348364
JAMA45151996015540111212287
Oncol.483019960155831525502156015558123150171
2019;5(7):1043-1047.7502156015563124179232253315345406440459510565630687725779834899955962
24.5502314015767128154
Willemsen73223160155105133158183245349395458525
M,12862316015599122
Melief14362316015599162188213274307
CJM,17712316015573120219241
Bekkenk20412316015564126179235295363416
MW,24862316015599203218
and27322316015557125195
Luiten29552316015557123148187246314
RM.32982316015563164187
Targeting35132316015559107144212274312338405475
the40162316015539107169
PD-1/PD-L142132316015564144186240277342422464523574
Axis48162316015574133159204
in550247601552795
Human6732476015582149254311378
Vitiligo.1080247601556694133158184208278346366
Front1474247601556194160229266
Immunol.17682476015528132236303371439466487
2020;11:579022.22842476015563123181242263315362375437496555619677738759
25.5502634015767131153
Lebbé7302636015556115184253315
C,1073263601557191
Meyer11912636015599160214274309
N,15272636015581101
Mortier16552636015598166202243268328363
L,2045263601555677
et2150263601556097
al.2275263601555680100
Evaluation24022636015559113170195260316352376442510
of2939263601556798
Two30642636015558141207
Dosing32982636015582149195218284352
Regimens36782636015563124193217320381447492
for4197263601553297133
Nivolumab43582636015580104160226251317420476544
in4929263601552591
CombinationWith5502796015574139243311336402458494518584652780806843910
Ipilimumab1487279601552290115139163266331434490559
in2073279601552288
Patients21882796015560114151175235302337385
With260027960155101127164231
Advanced28582796015571137194251317373431501
Melanoma:33862796015595156181237303370474530548
Results39622796015560121166231255293340
From4329279601555587152256
the46122796015535101162
Phase480127960155601251815502956015548109
IIIb/IV68729560155265074142184210274
CheckMate9882956015573139200257308410466502560
51115752956015563115161
Trial.1764295601555986111166190210
J20012956015544
Clin2072295601557397120186
Oncol.22852956015586154210274299319
2019;37(11):867-875.26312956015562121176227247308363388442488510528589650707737799856913930
26.5503114015767129156
Hommes7343116015578146251355417464
JW,12263116015540146160
Verheijden14143116015562119156224286311336405467534
RJ,19773116015561108127
Suijkerbuijk21333116015555121147172224284321391459484509562
KPM,27233116015560126222244
Hamann29953116015578135239296363430
D.3454311601557997
Biomarkers3579311601556186154259316352406466502550
of4157311601556597
Checkpoint42833116015569136198256309381450476543579
Inhibitor4891311601552390550327601557095164190229295332
Induced911327601552997167233290350420
Immune-Related13603276015530134239306373435476542604630687725784855
Adverse22433276015579147205266302350412
Events-A26833276015563119180248285334370443
Comprehensive31553276015574140245315352412480542610656681738799
Review.39833276015568130187213275367384
Front4395327601556396162231268
Oncol.46913276015590159216281308329
2020;10:585311.5503436015563124182242263315370392455515575634688735749
27.5503594015767129141
Teulings7193596015566119186212237304374419
HE,11673596015586145167
Limpens1362359601556389193263326394440
J,1830359601555069
Jansen19283596015549106174220282350
SN,23063596015565144166
et25003596015568106
al.2635359601556389110
Vitiligo-like2774359601557198137163188213282350391419443496557
depigmentation33593596015575137207233303407469537574632670695763831
in4219359601553299
patients43473596015576134172197259327364412
with47883596015598124163231
stage550375601554889147216278
III-IV85737560155255176115143209
melanoma109437560155105167193250318386491548
receiving1671375601553696154214239297323390460
immunotherapy21593756015525130234301369437475543605641700770825
and30123756015557125194
its3235375601552564112
association33763756015557103149218276301357395420488556
with39613756015591118156224
survival:42143756015546112149211237295353379398
a46413756015556
systematic4726375601554910615419425455039160155106164201227283
review862391601553898155182243335
and12263916015559126196
meta-analysis.145139160155106168207265304361429486511567615639685707
J21873916015545
Clin2260391601557499124192
Oncol.24803916015587156213279306327
2015;33(7):773-781.28353916015564124180232248311369399461494513572633694732786845901915
28.5504074015767131158
Fujisawa7364076015558122148173218277368426
Y,1191407601556274
Yoshino12934076015563123169237262329397
K,1719407601556286
Otsuka18344076015584125174240293353
A,2215407601557397
et2340407601556199
al.2468407601555681103
Retrospective25994076015563125163200267313383446504546572629690
study3317407601554686154224280
of3626407601556699
advanced37534076015556126184242310367426497
melanoma427940760155103165192248316384490547
patients48544076015569128522087601554066127195232281
treated552987601554986146202239299370
with59278760155102128167235
ipilimumab6191876015535105131156181285352456514583
after680387601556799143203240
nivolumab:7071876015578103161227254321425482552572
Analysis7672876015584152209235291338363408
of8109876015577110
608248876015571134
Japanese8411876015553110179238305368415477
patients.8916876015580139176202263331368417439
J9384876015553
Dermatol9465876015592155192522010360155106164201267293
Sci.55421036015560117142164
2018;89(1):60-66.57341036015564124180234253316377410465488507571634676742806828
29.52201194015767131153
Weber540111960155103161231294331
JS,5760119601554197118
Hodi59061196015578146217242
FS,61761196015556112133
Wolchok633711960155102167194250318386440
JD,68051196015541123140
et6974119601555997
al.7100119601555480101
Safety72291196015556115147208246306
Profile7564119601556196162192224249311
of7903119601556598
Nivolumab80291196015579104162229255322426483553
Monotherapy:86111196015596165233302339407469506564634689711
A93511196015571
Pooled945111960155651301995220135601552889160
Analysis54091356015576144201226282330354400
of58371356015569102
Patients59681356015565121159184246314351399
With639613560155106134172240
Advanced66651356015576144202260328385444515
Melanoma.720913560155101163189246314382487545567
J78041356015545
Clin78771356015574100124192
Oncol.80971356015588157214279306327
2017;35(7):785-792.84521356015564124180231245308366395457490509568627687726780839898918
30.52201514015767131157
Haratani54051516015589146183241278336404429
K,5863151601557196
Hayashi59871516015589146200259305372397
H,64131516015588109
Chiba65511516015581148173243301
Y,6881151601557283
et69931516015569108
al.7129151601556692113
Association72701516015583132178247305330386424449517585
of78841516015576109
Immune-Related80211516015534138243310378440480546609635692729789859
Adverse89091516015582151209269306353416
Events93531516015567123184252289338
With522016760155107134173241
Nivolumab54891676015583108166233259326431488558
Efficacy6075167601556191124157214272329389
in6492167601552795
Non-Small-Cell66151676015583152220259314418475501526564642701727752
Lung73961676015558124192261
Cancer.76861676015574132200257316353369
JAMA80831676015545116216292
Oncol.84031676015587156213279305326
2018;4(3):374-378.87581676015563124179234253315348408436455518574627667724780839862
31.52201834015766123142
Ishihara5390183601552368134158225281317374
H,5792183601557797
Takagi59171836015555103155214282307
T,6252183601555567
Kondo63471836015560126193262329
T,6704183601555567
et6799183601555896
al.692318360155547999
Association70501836015571119165232289314369406431497565
between76431836015566129166261321383450
immune-related81211836015522125229294361422462499559584640677736805
adverse89541836015554123180240275322384
events93651836015558114174241277325
and52201996015559127196
prognosis54451996015581118184255323391438462508
in59811996015537104
patients61141996015581139176202263331368417
with655919960155104130169237
metastatic682419960155116178217275321361419457482539
renal73911996015548108176233259
cell76781996015567127153178
carcinoma78851996015567125161216241309377482539
treated8453199601554986147203240300370
with885219960155103129168236
nivolumab.91161996015579104162229256322427484554574
Urol52202156015581117183210
Oncol.54592156015587156213278305326
2019;37(6):355.e21-355.e29.581421560155631231792312523153713984574875065696276847037658268819139701028108511041166122712871304
32.52202314015767128155
Xing5403231601557196164233
P,5665231601556569
Zhang57622316015570137194262332
F,6122231601556067
Wang621723160155107162230299
G,65452316015580103
et66762316015563102
al.6806231601555984106
Incidence6940231601552795152177246308376433492
rates7461231601553896134193240
of77302316015569102
immune-related78602316015527131236303370432473511571597654692751822
adverse87102316015559129187247284332394
events91322316015563120181249286334
and94952316015558126196
their52202476015540108170196232
correlation54802476015557122160197257284340378403471540
with60482476015592119157225
response6302247601553797144213283351397459
in6790247601552693
advanced69112476015558128186244312368428499
solid74382476015547115142167236
tumours77032476015538106211279347383431
treated8162247601553976136193230290360
with85512476015592118157225
NIVO88052476015581107172257
or90902476015568105
NIVO+IPI:92242476015581107172257334358422446466
a52202636015559
systematic53072636015549107154194254359416453479535
review5871263601553898155182243335
and62352636015559126196
meta-analysis.646026360155106168207265304361429486511567615639685707
J71962636015545
Immunother72692636015528132237303371439477545607644
Cancer.79412636015574133200257317353369
2019;7(1):341.83382636015564124180232253311338394417436499562614628
33.52202794015767126149
Fiala5394279601556688142165220
O,56392796015593108
Sorejs57732796015566132167224247290
O,60892796015593108
Sustr62232796015566129173210245
J,6494279601555067
et65872796015569104
al.6717279601556588107
Immune-related68502796015533134236301366425463499556580634669726794
Adverse76702796015582147203261295340399
Effects8095279601556696131190245285331
and84522796015564129197
Outcome86742796015593159196247310413473
of91722796015575106
Patients93042796015570124159182241306340386
With522029560155107131167233
Cancer54792956015568123188243300333
TreatedWith5838295601555580138192227284352478503539604
Immune64682956015521123225289355414
Checkpoint69082956015568133192248298368435458523557
Inhibitors.7491295601552186151174241264300363398443463
Anticancer79802956015570135170193246302367421478512
Res85182956015560119164
2020;40(3):1219–1227.87072956015558116171229247306368399455481498547596649698763814863922978983
34.52203114015767134161
Ascierto54103116015575125184210273311355422
PA,58623116015564131156
Del60473116015583147175
Vecchio62513116015565124183239308334403
M,66843116015599123
Robert68373116015564133205270308352
C,7219311601557395
et73443116015561101
al.7475311601555784107
Ipilimumab7612311601552596124150176282350456514586
1082273116015562119
mg/kg837531160155105176223280349
versus87533116015558120157206274321
ipilimumab9104311601552596124150176282350456514586
3mg/kg52203276015563189260307363432
in5682327601552493
patients58053276015569129167194257326364414
with62493276015591119159228
unresectable65073276015566135173234283346405449508579607671
or72073276015567105
metastatic734232760155104167207267314356415454481538
melanoma:791032760155104167195253322392498557578
a85183276015556
randomised,8604327601553999168239308415442488552624646
double-92803276015568137206277305368410
-blind,52203436015539112140166234305327
multicentre,557734360155108176203243270328388457496534596616
phase62233436015573143201249312
365653436015565
trial.6660343601554179107164191214
Lancet69043436015559120189247308348
Oncol.72813436015589159218284312335
2017;18(5):611-622.76463436015564126183235251305360394454487507572626674707775835898920
35.52203594015767129153
Agrawal54013596015581149185244335393419
S,5848359601556586
Feng59623596015565125193263
Y,6253359601557082
Roy63633596015570138193
A,65853596015580104
et67183596015567106
al.6852359601556389110
Nivolumab69913596015587112170237263330435492562
dose75813596015575143190252
selection:78623596015553115141203261303328396465484
challenges,83753596015562130187212237299367437499546567
opportunities,89703596015574145215285322365433500526564590651698720
and52203756015559128198
lessons5447375601553799147194263332378
learned58543756015537100156193262325396
for62793756015544112149
cancer64573756015568127195252312349
immunotherapy.68353756015537142247315383452490559621658717788843859
Journal77233756015554123192229298356382
for81333756015544112149
immunotherapy83113756015537142247315383452490559621658717788843
of91833756015579113
cancer.93253756015567126194252312349365
2016;4:72-72.52203916015563124179234254315335394455489544605625